Capital World Investors decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 81.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 2,029,750 shares of the biopharmaceutical company’s stock after selling 9,044,999 shares during the period. Capital World Investors owned about 0.16% of Gilead Sciences worth $143,666,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the business. Penserra Capital Management LLC boosted its stake in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 144 shares during the last quarter. American Beacon Advisors Inc. acquired a new stake in shares of Gilead Sciences during the first quarter valued at $143,000. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Gilead Sciences by 29.3% during the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 480 shares during the last quarter. Capstone Investment Advisors Netherlands B.V. acquired a new stake in shares of Gilead Sciences during the second quarter valued at $172,000. Finally, Sterling Investment Advisors Ltd. acquired a new stake in shares of Gilead Sciences during the second quarter valued at $184,000. 76.23% of the stock is currently owned by institutional investors.
In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the sale, the executive vice president now owns 77,363 shares in the company, valued at approximately $5,788,299.66. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total value of $6,054,372.48. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 494,999 shares of company stock valued at $37,404,139. 1.30% of the stock is owned by insiders.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.72 on Friday. The company has a market capitalization of $95,736.46, a PE ratio of 7.65, a P/E/G ratio of -1.23 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same quarter last year, the firm earned $2.75 EPS. Gilead Sciences’s quarterly revenue was down 13.2% on a year-over-year basis. research analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.86%. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.69%.
A number of analysts recently commented on the company. Argus raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a research note on Thursday, August 31st. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price objective on the stock. in a research note on Monday, August 28th. Wells Fargo & Company increased their price objective on Gilead Sciences from $73.00 to $81.00 and gave the company a “market perform” rating in a research note on Wednesday, September 6th. Oppenheimer assumed coverage on Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating on the stock. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research note on Thursday. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $85.11.
WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/08/capital-world-investors-lowers-holdings-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.